RxDoctor Payments Data

Ali Ebrahimi, MD

Interventional Cardiology · Birmingham, ALNPI 1467864827

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.7%), travel and lodging and grants — rather than concentrated in one kind of arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2024 at $19,544 and has fallen 71.6% since, to $5,558 in 2025. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,235in general payments, 2019–2025

Across 733 payments — averaging $75.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$13K
  • Abbott$10K
  • Medtronic$8K
  • Angiodynamics, Inc.$7K
  • Penumbra, Inc.$3K
  • Edwards Lifesciences$3K
  • plus $11K from 23 others
$50in research payments, 2019–2025

Across 1 payment — averaging $49.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$50

What the payments were for

  • Grants$13,83825%
  • Travel & lodging$14,49626%
  • Food & beverage$25,80847%
  • Education$1,0922%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,235 in reported general payments places this provider in the 90th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$19,994
Medicare patients
96
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$9,102

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →